Ma et al. (2020) demonstrated that baicalein inhibits the proliferation of prostate cancer cells and induces apoptosis by down-regulating the expression level of Ezrin. Baicalein has been found to inhibits the activity of 12-lipoxygenase (12-LOX), which consequently blocks the expression of vascular endothelial growth factor (VEGF) in prostate cancer cells, thereby effectively inhibits tumor angiogenesis (Nie et al., 2006). This evidence concerns the gene ALOX12 and Familial prostate cancer.